scispace - formally typeset
A

Ana M. Gonzalez-Angulo

Researcher at University of Texas MD Anderson Cancer Center

Publications -  261
Citations -  36571

Ana M. Gonzalez-Angulo is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 82, co-authored 260 publications receiving 32565 citations. Previous affiliations of Ana M. Gonzalez-Angulo include University of Texas Health Science Center at Houston.

Papers
More filters
Journal ArticleDOI

Comprehensive molecular portraits of human breast tumours

Daniel C. Koboldt, +355 more
- 04 Oct 2012 - 
TL;DR: The ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity.
Journal ArticleDOI

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

TL;DR: Assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to respond to trastuzumab-based therapy, and the combined analysis of PTEN and PIK3CA identified twice as many patients at increased risk for progression compared to PTEN alone.
Book ChapterDOI

Overview of Resistance to Systemic Therapy in Patients with Breast Cancer

TL;DR: The rates of local and systemic recurrence vary within different series, but in general, distant recurrences are dominant, strengthening the hypothesis that breast cancer is a systemic disease from presentation.
Journal ArticleDOI

Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer

TL;DR: Diabetic patients with breast cancer receiving metformin and neoadjuvant chemotherapy have a higher pCR rate than do diabetics not receiving meetformin, and additional studies to evaluate the potential of met formin as an antitumor agent are warranted.